Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab Combined With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)

Status: Recruiting
Phase: Phase 2
Diagnosis: Brain/Neuro Cancer: Recurrent Glioblastoma
NCT ID: NCT02017717 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-630

 

The purposes of the study are to understand the 1. Safety and tolerability of Nivolumab and Nivolumab in combination with Ipilimumab in a safety lead-in phase (Cohort 1, 1b) and 2. The safety, tolerability and efficacy of Nivolumab versus Bevacizumab (Cohort 2) in patients diagnosed with recurrent glioblastoma (GBM).

 

Conducting Institutions:
Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth-Israel Deaconess Medical Center

Overall PI:
David Reardon, MD, Dana Farber Cancer Institute

Site-responsible Investigators:
Jorg Dietrich, M.D., Massachusetts General Hospital
Eric Wong, MD, Beth Israel Deaconess Medical Center

Contacts:
Dana-Farber Cancer Institute: Lisa Doherty, ldoherty1@partners.org
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Beth-Israel Deaconess Medical Center: Cancer Trials Call Center, 617-667-3060

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Subjects with histologically confirmed Grade IV malignant glioma - Previous treatment with radiotherapy and temozolomide - Documented first recurrence of GBM - At least one measurable lesion - Karnofsky performance status (PS) ≥ 70 Exclusion Criteria: - More than one recurrence of GBM - Presence of extracranial metastatic or leptomeningeal disease - Active, known or suspected autoimmune disease - Prior Bevacizumab or other anti-vascular growth factor (VEGF) or anti-angiogenic treatment - Clinically significant cardiovascular disease
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients


    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us
award

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.

award

Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters